DAC-002 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DAC-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DAC-002 overview
DAC-002 is under development for the treatment of solid tumors including triple-negative breast cancer, small cell lung cancer. It is administered by intravenous drip. The drug candidate is an anti-Trop2 monoclonal antibody conjugated with an anti-tubulin Tubulysin B analog through a smart linker.
It was also under development for the treatment of non-small cell lung cancer and pancreatic cancer.
Hangzhou DAC Biotech overview
Hangzhou DAC Biotech Co. Ltd., a biopharmaceutical company and focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. The company is headquartered China.
For a complete picture of DAC-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
